Astellas Pharma Inc. ALPMY
16.40 USD +0.62 (+3.93%)
Nov 9, 2026, 11:46 AM EST
16.26 Day range 16.40
11.34 52-week range 17.35
- YTD
- +23.40%
- 1 year
- +43.48%
- Market cap
- 29.41B
- EPS (ttm)
- 1.36
- P/E ratio
- 12.06
- YTD return
- +23.40%
- 1-year return
- +43.48%
- Volume
- 3.87K
- Avg volume
- 97.82K
- Open
- 16.26
- Previous close
- 15.78
- Day's range
- 16.26 – 16.40
- 52-week range
- 11.34 – 17.35
- Earnings date
- Oct 29, 2026
2Y +5.70 (+53.27%)
Next earnings
Oct 29, 2026
Expected Oct 29, 2026. Consensus EPS estimate 0.3912.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 29, 2026 | Sep 30, 2026 | 0.3912 | — | — | — |
| Aug 5, 2026 | Jun 30, 2026 | 0.3363 | 0.503 | +0.17 | +49.57% |
| Apr 27, 2026 | Mar 31, 2026 | 0.1941 | 0.1521 | -0.04 | -21.64% |
| Feb 4, 2026 | Dec 31, 2025 | 0.2916 | 0.364 | +0.07 | +24.83% |
| Oct 30, 2025 | Sep 30, 2025 | 0.1993 | 0.30 | +0.10 | +50.53% |
| Jul 30, 2025 | Jun 30, 2025 | 0.1356 | 0.40 | +0.26 | +194.99% |
News
Is Astellas Pharma (ALPMY) Outperforming Other Medical Stocks This Year? 
Merck Advances European Regulatory Approval For Keytruda Combination In Bladder Cancer 
These Analysts Boost Their Forecasts On Vir Biotechnology 
Vir Biotechnology Stock Hits 52-Week High Tuesday - Here's Why 
Why Is Monte Rosa Stock Trading Higher Today? 
Why Is Taysha Gene Therapies Stock Falling Friday? 
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024 
From AI to Obesity Drugs - Global Pharma Has $700B For M&A and Investments: Goldman Sachs 
Stocks That Hit 52-Week Highs On Tuesday - Stocks That Hit 52-Week Highs On Tuesday
Your note
Sign in to keep a note on ALPMY — it syncs with the Stock Master app.